TGM2 and melanoma: TG2 was discovered to be the ECM-ligand of GPR56 in melanoma tissues where it was shown that the binding of TG2 to the receptor initiated internalization and lysosomal degradation of TG2, resulting in decreased fibronectin deposition in the ECM (13, 15, 30).